Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18708182 | 1.00 | P2RY12 (0.38) | P2RY12PRMT6 | |
| SCHEMBL18503745 | 0.83 | ADORA2A (0.47) | P2RY12 | |
| SCHEMBL18708181 | 0.83 | ADORA2A (0.47) | P2RY12 | |
| SCHEMBL18503734 | 0.83 | ABL1 (0.32) | — | |
| SCHEMBL18708173 | 0.83 | ABL1 (0.32) | — | |
| SCHEMBL18503744 | 0.82 | BMPR1B (0.43) | P2RY12PRMT6 | |
| SCHEMBL18708183 | 0.82 | BMPR1B (0.43) | P2RY12PRMT6 | |
| SCHEMBL13164828 | 0.82 | PRMT6 (0.35) | P2RY12PRMT6 | |
| SCHEMBL12851767 | 0.81 | PRMT6 (0.36) | P2RY12PRMT6 | |
| SCHEMBL18510987 | 0.78 | PRMT6 (0.36) | P2RY12PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044528-A1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | OSAKA UNIVERSITY (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044528-A1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | NSUN2, NCL, NSUN3 | P2RY12 2878/4885PRMT6 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.